Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) EBIT (2016)

Historic EBIT for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to -$42.2 million.

  • Tenax Therapeutics' EBIT fell 24887.04% to -$42.2 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$63.5 million, marking a year-over-year increase of 2819.9%. This contributed to the annual value of -$19.5 million for FY2024, which is 13675.01% down from last year.
  • Latest data reveals that Tenax Therapeutics reported EBIT of -$42.2 million as of Q4 2016, which was down 24887.04% from -$4.5 million recorded in Q3 2016.
  • In the past 5 years, Tenax Therapeutics' EBIT registered a high of $68.9 million during Q2 2012, and its lowest value of -$74.1 million during Q2 2013.
  • Over the past 4 years, Tenax Therapeutics' median EBIT value was -$3.2 million (recorded in 2012), while the average stood at -$7.5 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 242467.64% in 2012, then tumbled by 24887.04% in 2016.
  • Tenax Therapeutics' EBIT (Quarter) stood at -$682843.0 in 2012, then crashed by 10746.09% to -$74.1 million in 2013, then surged by 83.66% to -$12.1 million in 2015, then tumbled by 248.87% to -$42.2 million in 2016.
  • Its EBIT stands at -$42.2 million for Q4 2016, versus -$4.5 million for Q3 2016 and -$4.7 million for Q2 2016.